General Information of Drug (ID: DMO792L)

Drug Name
2-amino-uridine-5'-monophosphate Drug Info
Synonyms iso-CMP; compound 13g [PMID: 21417463]
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
49867142
TTD Drug ID
DMO792L

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Discontinued Drug(s)
Investigative Drug(s)
Drug(s) Targeting P2Y purinoceptor 4 (P2RY4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
INS 316 DMTHMEI Lung cancer 2C25.0 Discontinued in Phase 3 [2]
PPADS DMWHN3T Discovery agent N.A. Investigative [3]
UTPgammaS DMKLB4O Discovery agent N.A. Investigative [4]
CTP DM4T62U Discovery agent N.A. Investigative [2]
ITP DMVFITX Discovery agent N.A. Investigative [2]
MRS2927 DMB2A7Q Discovery agent N.A. Investigative [5]
MRS4062 DMWKXGP Discovery agent N.A. Investigative [5]
N4-phenylethoxycytidine-5'-triphosphate DM7KX2V Discovery agent N.A. Investigative [5]
(N)methanocarba-UTP DM6SV7I Discovery agent N.A. Investigative [6]
⏷ Show the Full List of 9 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
P2Y purinoceptor 4 (P2RY4) TT24DGP P2RY4_HUMAN Agonist [1]

References

1 Structural modifications of UMP, UDP, and UTP leading to subtype-selective agonists for P2Y2, P2Y4, and P2Y6 receptors. J Med Chem. 2011 Apr 28;54(8):2878-90.
2 ATP, an agonist at the rat P2Y(4) receptor, is an antagonist at the human P2Y(4) receptor. Mol Pharmacol. 2000 May;57(5):926-31.
3 Development of selective agonists and antagonists of P2Y receptors. Purinergic Signal. 2009 Mar;5(1):75-89.
4 Enzymatic synthesis of UTP gamma S, a potent hydrolysis resistant agonist of P2U-purinoceptors. Br J Pharmacol. 1996 Jan;117(1):203-9.
5 Pyrimidine nucleotides with 4-alkyloxyimino and terminal tetraphosphate delta-ester modifications as selective agonists of the P2Y(4) receptor. J Med Chem. 2011 Jun 23;54(12):4018-33.
6 Methanocarba modification of uracil and adenine nucleotides: high potency of Northern ring conformation at P2Y1, P2Y2, P2Y4, and P2Y11 but not P2Y6 receptors. J Med Chem. 2002 Jan 3;45(1):208-18.